Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy

• DOI: 10.3389/fcell.2021.638312
• Publication Date: 2021-03-15T05:31:22Z
• Authors: Xiaona Fan; Dan Wang; Wenjing Zhang; Jinshuang Liu; Chao Liu; Qingwei Li; Zhigang Ma; Hengzhen Li; Xin Guan; Yibing Bai; Jiani Yang; Changjie Lou; Xiaobo Li; Guangyu Wang; Zhiwei Li
• Keywords: PFS; Cell and Developmental Biology; 03 medical and health sciences; response; 0302 clinical medicine; QH301-705.5; inflammatory biomarker; anti–PD-1 therapy; advanced gastric and colorectal cancer; Biology (General); 3. Good health

There is a lack of useful biomarkers for predicting the efficacy anti–programmed death-1 (PD-1) therapy advanced gastric and colorectal cancer. To address this issue, in study we investigated correlation between inflammatory marker expression survival patients with Data 111 cancer treated anti–PD-1 regimens were retrospectively analyzed. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte (MLR), platelet-to-lymphocyte (PLR), clinical characteristics each patient selected as main variables. Overall response rate, disease control progression-free primary endpoints, overall immune-related adverse events (irAEs) secondary endpoints. The chi-squared test Fisher’s exact used to evaluate relationships categorical Uni- multivariate Cox regression analyses performed, median estimated Kaplan–Meier method. rate anti–PD-1therapy tumors 12.61 66.66%, respectively. MLR < 0.31, NLR 5, PLR 135 had significantly higher than those > ( P 0.05). analysis revealed that BMI 18.5, first-line associated prolonged PFS. 0.31 18.5 survival. irAE differed groups, was an increased irAEs = 0.028). These results indicate markers NLR, MLR, have utility or risk